"Tracking Baker Brothers Portfolio – Q1 2018 Update"
"Baker Brothers’ 13F portfolio value increased from $11.54B to $11.80B.BeiGene stake was increased during the quarter.The top-three positions are Incyte Corporation, Seattle Genetics, and BeiGene and they add up to almost ~55% of the portfolio.This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers’ 13F portfolio on a quarterly basis. It is based on Baker Brothers’ regulatory 13F Form filed on 05/14/2018.This quarter, Baker Brothers’ 13F portfolio increased ~2% from $11.54B to $11.80B. The top three holdings are at ~55% while the top five holdings are close to ~68% of the 13F assets: Incyte Corporation (INCY), Seattle Genetics (SGEN), BeiGene (BGNE), Alexion Pharmaceuticals (ALXN), and BioMarin Pharmaceuticals (BMRN).The spreadsheet below highlights changes to Baker Brothers’ 13F holdings in Q1 2018. For a look at how the portfolio has progressed, please see our :To learn more about how to profit from a strategy of following the best hedge fund picks, check out our book .Regulatory Filings thru 3/20/2018: Form 4 3/15/2018 & 13D/A 3/6/2018 – IDRA – Idera Pharma – 20.25K shares acquired at $0.47 – warrant exercise – 39M shares (18% of business) – also has ~22M warrants that expire from May 2020 to 2021, Form 4 & 13D/A – 3/12/2018 – GHDX – Genomic Health – minor director share exercise 8.2K shares, 13.9M shares – 40% of business, 13G & 13G/A’s filed  on 2/13/2018: Contrafect – CFRX – 7.4M – 10% of business, Ritter Pharma – RTTR – 2.8M – 5.7% of business, Ascendis Pharma – ASND – 2.6M – 7.1% of business, Ablynx NV – ABLX – 4.6M – 6.2% of business, Heron Therapeutics – HRTX – 4.9M  - 7.3% of business, Trillium Therapeutics – TRIL – 668K – 5% of business, Versartis – VSAR – 1.45M – 4% of business, Rhythm Pharma – RYTM – 2M – 7.5%, Aevi Genomic Medicine – GNMX – 4M – 6.8%, CymaBay Therapeutics – CBAY – 3M – 6.8% of business, BioCryst Pharma – BCRX – 14M – 14.3%, Aeglea Bio Therapeutics – AGLE – 1.1M – 6.8%, Tonix Pharma – TNXP – 670K – 8.9%, Sangamo Therapeutics – SGMO – 2.1M – 2.5%, Arcturus Therapeutics – ARCT – zero, Catalyst Pharma – CPRX – 5.9M – 5.7%, Cerus Corp – CERS – 9.8M – 8.5%, Amerin Corp – AMRN – 22.7M – 8.4%, Acorda Therapeutics – ACOR – 206K – 0.4%, 13D/A & Form 4 – 2/5/2018 – SGEN – 50M – 32% - 3.85M shares acquired at $52."